Lundbeck’s Vyepti (eptinezumab) has received NICE recommendation for the prevention of migraine in adults experiencing four or more migraine days monthly who have been tre
Japanese pharma group Eisai says it is battling a ransomware attack that was launched last weekend and has resulted in some of its servers becoming encrypted.
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas